End-of-day quote
Other stock markets
|
||
- GBX | - |
Apr. 24 | BMO Capital Adjusts Price Target on Novartis to $116 From $114, Maintains Market Perform Rating | MT |
Apr. 24 | Novartis Says New Malaria Drug Formulation Safe and Effective for Babies | MT |
Financials (USD)
Sales 2024 * | 48.79B | Sales 2025 * | 50.63B | Capitalization | 199B |
---|---|---|---|---|---|
Net income 2024 * | 10.23B | Net income 2025 * | 11.85B | EV / Sales 2024 * | 4.33 x |
Net Debt 2024 * | 12.19B | Net Debt 2025 * | 10.9B | EV / Sales 2025 * | 4.15 x |
P/E ratio 2024 * |
19.5
x | P/E ratio 2025 * |
16.7
x | Employees | - |
Yield 2024 * |
3.69% | Yield 2025 * |
3.83% | Free-Float | 81.95% |
Latest transcript on NOVARTIS
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 48 | 04-12-31 | |
Director of Finance/CFO | 59 | 02-12-31 | |
Shreeram Aradhye
CTO | Chief Tech/Sci/R&D Officer | 62 | 22-05-15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bill Winters
BRD | Director/Board Member | 62 | 12-12-31 |
Simon Moroney
BRD | Director/Board Member | 65 | 20-02-27 |
Chairman | 68 | 12-12-31 |
1st Jan change | Capi. | |
---|---|---|
+25.61% | 672B | |
+25.87% | 570B | |
-5.24% | 360B | |
+16.49% | 321B | |
+8.28% | 300B | |
+7.09% | 217B | |
-9.12% | 204B | |
-8.75% | 149B | |
-5.21% | 147B |
- Stock Market
- Equities
- NOVN Stock
- 0HKE Stock